Abstract:Background: Dendritic cells (DCs) are the most potent antigen-presenting cell population for activating tumor-specific T cells. Due to the wide range of methods for generating DCs, there is no common protocol or defined set of criteria to validate the immunogenicity and function of DC vaccines. Methods: Monocyte-derived DCs were generated during 4 days of culture with recombinant granulocyte-macrophage colony stimulating factor and interleukin-4, and pulsed with tumor lysate produced by hypochlorous acid oxidation of tumor cells. Different culture parameters for clinical-scale DC preparation were investigated, including: 1) culture media; 2) culture surface; 3) duration of activating DCs with lipopolysaccharide (LPS) and interferon (IFN)-gamma; 4) method of DC harvest; and 5) cryomedia and final DC product formulation. Results: DCs cultured in CellGenix DC media containing 2% human AB serum expressed higher levels of maturation markers following lysate-loading and maturation compared to culturing with serum-free CellGenix DC media or AIM-V media, or 2% AB serum supplemented AIM-V media. Nunclon™Δ surface, but not Corning(®) tissue-culture treated surface and Corning(®) ultra-low attachment surface, were suitable for generating an optimal DC phenotype. Recombinant trypsin resulted in reduced major histocompatibility complex (MHC) Class I and II expression on mature lysate-loaded DCs, however presentation of MHC Class I peptides by DCs was not impaired and cell viability was higher compared to cell scraping. Preservation of DCs with an infusible cryomedia containing Plasma-Lyte A, dextrose, sodium chloride injection, human serum albumin, and DMSO yielded higher cell viability compared to using human AB serum containing 10% DMSO. Finally, activating DCs for 16 hours with LPS and IFN-γ stimulated robust mixed leukocyte reactions (MLRs), and high IL-12p70 production in vitro that continued for 24 hours after the cryopreserved DCs were thawed and replated in fresh media. Conclusions: This study examined criteria including DC phenotype, viability, IL-12p70 production and the ability to stimulate MLR as metrics of whole oxidized tumor lysate-pulsed DC immunogenicity and functionality. Development and optimization of this unique method is now being tested in a clinical trial of autologous oxidized tumor lysate-pulsed DC in clinical-scale in recurrent ovarian, primary peritoneal or fallopian tube cancer (NCT01132014).

Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing

Cytokine-Induced Killer (cik) Cell Therapy for Patients with Hepatocellular Carcinoma: Efficacy and Safety

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate

Cytokine-induced Killer Cells Co-Cultured with Non-Cell Derived Targeting Peptide-Loaded Dendritic Cells Induce a Specific Antitumor Response.

The Clinical Research of Cytokine-induced Killer Cells Co-culturing with Autologous Dendritic Cells on the Clinical Immunotherapy for

In vitro Production of Dendritic Cells as Cancer Immunotherapy: Highlights on Sample Source, Culture Period, Differentiation and Maturation Cytokines

2003-2013, a Valuable Study: Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Stage IV Breast Cancer.

Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells

High-throughput proliferation and activation of NK-92MI cell spheroids via a homemade one-step closed bioreactor in pseudostatic cultures for immunocellular therapy

Predictive Significance of T Cell Subset Changes During Ex Vivo Generation of Adoptive Cellular Therapy Products for the Treatment of Advanced Non-Small Cell Lung Cancer

Abstract 3180: Targeting Peptide-Loaded-dc CIK Cells Induce a Specific Antitumor Response

Generation of Large Numbers of Dendritic Cells and Cytokine-induced Killer Cells from Breast Cancer Patients

Preparation of DC-CIK Using EBV Peptide-Pulsed DC from Peripheral Blood Mononuclear Cells of Post-Transplant Lymphoproliferative Disorder Patients after Hematopoietic Stem Cell Transplantation

Dendritic Cells Loaded with U251 Tumor Cell Antigen Enhance the Cytotoxic Effect of Cytokine-Induced Killer Cells Against U251 Cell Line

[The Anti-Tumor Effects of Dendritic Cells Co-Cultured with Cytokine Induced Killer Cells after Chemotherapy].

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

CD8 + chimeric antigen receptor T cells manufactured in absence of CD4 + cells exhibit hypofunctional phenotype

Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy

Optimization and Validation of a Harmonized Protocol for Generating Therapeutic-Grade Dendritic Cells in a Randomized Phase II Clinical Trial, Using Two Varied Antigenic Sources